Dear Editor, we read the publication on “The expression of RUNX3 gene in renal cell cancer and its clinical relevance with serum vascular endothelial growth factor” with a great interest. Parmar et al. concluded that “Lower expression of RUNX3 in renal cancer suggests its tumor suppressive role”. In fact, the role of RUNX3 is well clarifi d in several malignancies. It is no doubt there is the similar observation for the case of renal cell carcinoma. In the present report, there are some limitations as noted by Parmar et al. An important consideration is the possible concurrent effect of another genetic factor that might modify the fi phenotypic manifestation. In case of RUNX3, the effect of concurrent p53 is well clarifi and should be studied.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.